Therapeutics

siRNA
#Biotechnology platform #Eleven Therapeutics #Seed funding #siRNA #Therapeutics #Undecimal Bio

Seed financing to address ‘liver trap’ in siRNA therapeutic delivery 

Undecimal Bio, a platform biotechnology company advancing targeted delivery of siRNA therapeutics, has announced an oversubscribed $18 million seed financing.   The company is a spin-out from Eleven Therapeutics and will use the funding to expand DELiveri, its AI-enabled platform for identifying conjugates that can direct RNA… Read More

#News

3d structure of the protein molecule
#AI #Drug design #Protein targets #Therapeutics

Galux raises $29m to advance AI-driven protein therapeutics 

Galux, a company using AI to drive drug design, has raised $29 million to support its protein therapeutics platform.  The Series B financing round brought together existing investors, including InterVest, DAYLI Partners, and PATHWAY Investment, with new investors Yuanta Investment, Korea Development Bank (KDB), SL Investment, NCORE Ventures, SneakPeek Investments, Korea Investment & Securities,… Read More

#Business & Investment #News

#Ajna Biosciences #Botanical #Drug development #Plant-based #Therapeutics

New podcast: Redefining the future with plant-based therapeutics

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Joel Stanley, CEO… Read More

#News

#Defense Innovation Agency (AID) #Funding #Human pathogens #National Research Agency (ANR) #Therapeutics #Tropical disease

Grant funding worth nearly €800,000 to develop antiviral awarded

France’s National Research Agency (ANR) and Defense Innovation Agency (AID) will finance the BUNYANTIVIR project to introduce a novel therapeutic approach for Bunyaviricetes’ class of human pathogenic viruses found in tropical and subtropical regions. The BUNYANTIVIR project has been selected under the call for proposals for the 2024 ASTRID Maturation… Read More

#News

Cancer research
#ASCO #Cancer immunotherapy #Cancer research #Cell therapy #Oncology #Precision medicine #Therapeutics

Expert commentary from ASCO 2025

This year’s American Society of Clinical Oncology (ASCO) Annual Meeting took place at the McCormick Place Convention Center in Chicago from 30 May to 3 June 2025. DDW’s Megan Thomas collected commentary from industry experts in attendance. CCR8 therapies gain clinical significance Stephan Schann is Chief Scientific Officer at Domain… Read More

#Cancer Research #Exclusive Content

#Collaboration #Deep Science Ventures #Fibrosis #Finance #General Inception #Therapeutics

Venture partners create fibrosis-focused therapeutics company

Venture studios Deep Science Ventures and General Inception have announced plans to create a company focused on developing novel treatments for fibrosis. Science Ventures and General Inception’s European arm, Igniter Europe, aim to establish a company dedicated to overcoming current bottlenecks in fibrosis therapeutics by developing a novel concept and… Read More

#Business & Investment #News

#mRNA #mRNA-based vaccines #Promega #Therapeutics

Bridge innovation to implementation with high-quality RNA therapeutic raw materials 

This article is sponsored by Promega. In today’s fast-paced RNA therapeutic development landscape, experience matters. With over 40 years of experience in RNA synthesis by in vitro transcription (IVT), Promega smooths the transition from research to production by reducing risk and saving time, without compromising the quality of RNA synthesis… Read More

#News

#2024 predictions #Stem cell transplant #Stem cells #Therapeutics

2024 predictions: Experts weigh in on stem cells  

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on the future of stem cells in drug discovery.   Melissa Little, CEO of the Novo Nordisk Foundation Centre for Stem Cell Medicine  “In the stem cell space, 2023 has seen significant increases in the delivery… Read More

#Exclusive Content

Cancer Abnormal Cells Nucleus Genetic Division Infection Microscope
#Cancer #Cancer research #Curve Therapeutics #Therapeutics

Research supports HIF inhibition as a therapeutic approach for cancer 

Curve Therapeutics’ CSO Ali Tavassoli has published an article in the Journal of the American Chemical Society (JACS) which highlights the potential of HIF inhibition as a therapeutic approach for cancers. The paper is titled ‘Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors (HIF) 1 and… Read More

#Cancer Research #News

Business acquisition
#Cell and gene therapy #Genetic engineering #Ginkgo Bioworks #Patch Biosciences #RNA #Therapeutics

Ginkgo acquires machine learning biotech Patch Biosciences

Ginkgo Bioworks has acquired Patch Biosciences, with the intention to strengthen its gene therapy services, cell therapy services, and RNA therapeutics services.  Ginkgo provides R&D services across industries, including in biopharma, and will incorporate Patch’s machine learning models and downstream assays into its existing platform, making new… Read More

#News

2024 predictions, road forward
#2024 predictions #AstraZeneca #BioSenic #Cancer #Drug discovery #Mosaic Therapeutics #Oncology #OrganaBio #Phesi #Therapeutics

2024 predictions: Experts weigh in on cancer research

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on what to expect from cancer research and immunotherapies. Greg Rossi, Senior Vice… Read More

#Cancer Research #Exclusive Content #Opinion #Trends & Analysis

Fibrosis lungs
#Fibrocor Therapeutics #Fibrosis #Fibrotic disease #Small molecules #Therapeutics

Fibrosis research: Advances and challenges 

Fibrocor Therapeutics, a developer of novel therapeutics to treat fibrosis, recently appointed Piet Wigerinck as Chief Scientific Advisor. Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. DDW’s Megan Thomas caught up with Wigerinck to learn more about his work with small molecules for fibrosis research.   MT:… Read More

#Exclusive Content #Opinion

#Drug discovery #Plant-based #Therapeutics

Where is the promise for plant-based medicines? Part 3 

In the third and final part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates therapeutic breakthroughs using plant-based products in drug discovery. The first part of the series explored medical cannabis, and the second looked into psylocibin.   Green tea   Epigallocatechin gallate (EGCG), also known as… Read More

#Exclusive Content #Opinion #Regulatory

Cancer cells
#AACR 2023 #Cancer research #DDW Events podcast #Kintara Therapeutics #Meet the Researcher #Therapeutics

New vodcast: Dennis Brown, Kintara Therapeutics, at AACR 2023

At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. In this vodcast episode, Thomas speaks with Dennis Brown, Chief Scientific Officer at Kintara Therapeutics. You… Read More

#News

Cancer cells
#AACR 2023 #Cancer research #DDW Events podcast #Kintara Therapeutics #Meet the Researcher #Therapeutics

Vodcast: Dennis Brown, Kintara Therapeutics, at AACR 2023

At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. In this vodcast episode, Thomas speaks with Dennis Brown, Chief Scientific Officer at Kintara Therapeutics. You… Read More

#Videos

AI and drug discovery
#Etcembly #Generative AI #Immunotherapy #T cell receptor (TCR) #Therapeutics

Etcembly announces immunotherapy drug designed by AI 

British techbio Etcembly is coming out of stealth mode, kickstarting the next generation of immunotherapies with a pipeline of T cell receptor (TCR) therapeutics designed using generative AI.  The company’s lead therapeutic programme, ETC-101, is the world’s first AI-designed bispecific T cell engager. It targets PRAME, a validated antigen present… Read More

#Business & Investment #News